<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691115</url>
  </required_header>
  <id_info>
    <org_study_id>1476-291-001</org_study_id>
    <nct_id>NCT04691115</nct_id>
  </id_info>
  <brief_title>AM1476/Placebo Study in Healthy Subjects</brief_title>
  <official_title>AM1476 - A Phase I, Double-blind, Placebo-controlled, Single- and Multiple-oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AnaMar AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AnaMar AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I, Double-blind AM1476/Placebo Study in Healthy Subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, randomised, placebo-controlled, single- and multiple-oral dose study conducted&#xD;
      in 2 parts, for evaluation of AM1476.&#xD;
&#xD;
      Part A will comprise a single-ascending dose, sequential-group design incorporating a&#xD;
      single-group, 2-period crossover arm incorporating a food-effect evaluation. Overall, 48&#xD;
      subjects will be studied in 6 groups, with each group consisting of 8 subjects.&#xD;
&#xD;
      Part B will comprise a multiple-ascending dose, sequential-group design. Overall, 24 subjects&#xD;
      will be studied in 3 groups, with each group consisting of 8 subjects.&#xD;
&#xD;
      The primary objective of the study is to determine the safety and tolerability of single- and&#xD;
      multiple-oral doses of AM1476 in healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2020</start_date>
  <completion_date type="Anticipated">June 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 26, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SAD part: sentinel dosing for 6 groups divided into 2 cohorts. MAD part: 3 groups Each group consists of 8 subjects, 6 will receive AM1476 and 2 will receive placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Through study completion, an average of 7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Laboratory Abnormalities</measure>
    <time_frame>Through study completion, an average of 7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of ECG Abnormalities</measure>
    <time_frame>Through study completion, an average of 7 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Safety</condition>
  <condition>Tolerability</condition>
  <arm_group>
    <arm_group_label>Active AM1476</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM1476 will be administered as capsules in an escalating manner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comparator will be administered as capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AM1476 - Placebo</intervention_name>
    <description>Oral drug administration</description>
    <arm_group_label>Active AM1476</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, of any race, between 18 and 60 years of age, inclusive.&#xD;
&#xD;
          -  A body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive.&#xD;
&#xD;
          -  In good health, no clinically significant findings from history, examination.&#xD;
&#xD;
          -  Females will not be pregnant or lactating,&#xD;
&#xD;
          -  Females of childbearing potential and males agree to use contraception.&#xD;
&#xD;
          -  Able to comprehend and willing to sign an ICF and to abide by the study restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history or clinical manifestation of any disorder.&#xD;
&#xD;
          -  History of significant hypersensitivity, intolerance, or allergy.&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection.&#xD;
&#xD;
          -  Positive hepatitis panel and/or positive human immunodeficiency virus test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley Brooks, MD, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ingegerd Dalfelt</last_name>
    <phone>+46 708 43 33 48</phone>
    <email>ingegerd.dalfelt@anamar.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helena Arozenius</last_name>
    <phone>+46 768 35 50 21</phone>
    <email>helena.arozenius@anamar.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Brooks</last_name>
      <phone>+441133013521</phone>
      <email>ashley.brooks@covance.com</email>
    </contact>
    <investigator>
      <last_name>Ashley Brooks, MD, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Ackroyd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

